Hepatite C

revisão dos medicamentos utilizados no tratamento

Palavras-chave: Hepatite C, Tratamento farmacológico, Interferons, Literatura de revisão como assunto, Diagnóstico

Resumo

O objetivo deste trabalho foi realizar uma revisão da literatura sobre os fármacos utilizados para o tratamento da hepatite C desde a descoberta do vírus, em 1989. Para atingir esse objetivo, foi realizada uma pesquisa nas bases Medline e SciELO, utilizando o termos “hepatite C”, “tratamento”, “livre de interferon”, “revisão” e “ensaio clínico”. Este trabalho apresenta uma revisão das características gerais da hepatite C juntamente com sua epidemiologia e diagnóstico. Durante muito tempo, a única opção disponível para o tratamento da hepatite C foi o interferon. Esta droga não mostrou boa eficácia e seu uso foi minimizado com o surgimento de novos regimes sem interferon que aumentaram a taxa de sucesso para algo em torno de 95%. Tais medicamentos permitiram o alcance real da cura do vírus, embora estejam disponíveis no Sistema Único de Saúde (SUS) brasileiro, são tratamentos caros que restringem o acesso a grande parte da população infectada.

Downloads

Não há dados estatísticos.

Biografia do Autor

Cássio Marques Perlin, Universidade Federal do Paraná (UFPR)

Graduação em Farmácia pela Universidade Federal do Mato Grosso do Sul-UFMS; Mestrado em Assistência Farmacêutica e Acadêmico do curso de Medicina pela Universidade Federal do Paraná - UFPR.

Anderson Dillmann Groto, Universidade Federal do Paraná (UFPR)

Acadêmico do curso de Medicina pela Universidade Federal do Paraná-UFPR.

Gustavo Olivo Perlin, Instituto de Defesa Agropecuária do Governo do Mato Grosso

Graduação em Medicina Veterinária e Mestrado em Ciência Animal pela Universidade Paranaense-UNIPAR; Fiscal Estadual de Defesa Agropecuária e Florestal do Governo do Estado do Mato Grosso, Brasil.

Mayara Angélica Bolson Salamanca, Universidade Federal do Paraná (UFPR)

Graduação em Medicina pela Faculdade Assis Gurgacz-FAG; Mestrado em Ensino nas Ciências da Saúde pela Faculdade Pequeno Príncipe-FPP; Médica do Programa Saúde da Família na Prefeitura de Toledo, Paraná; Docente do curso de Medicina na Universidade Federal do Paraná-UFPR.

Referências

Rodrigues Neto J, Cubas MR, Kusma SZ, Olandoski M. Prevalence of hepatitis C in adult users of the public health service of Sao Jose dos Pinhais--Parana. Rev Bras Epidemiol. 2012;15(3):627-38. doi:10.1590/S1415-790X2012000300016

Perlin CM, Ferreira VL, Borba HHL, Wiens A, Ivantes CAP, Lenzi L, et al. Quality of life in Brazilian patients with treated or untreated chronic hepatitis C. Rev Inst Med Trop Sao Paulo. 2017;59:1-7. doi: 10.1590/s1678-9946201759081.

Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol. 2017;9(33):1239-52. doi: 10.4254/wjh.v9.i33.1239.

Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis. 2013;13:60. doi: 10.1186/1471-2334-13-60

Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20(28):9270-80. doi: 10.3748/wjg.v20.i28.9270.

Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci. 2014;8(1):19-25. doi: 10.4103/0973-6247.126683.

Fonseca JC. History of viral hepatitis. Rev Soc Bras Med Trop. 2010;43(3):322-30. doi: 10.1590/S0037-86822010000300022

Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19(7):837-49. doi: 10.1038/nm.3248.

Heiat M, Ranjbar R, Alavian SM. Classical and modern approaches used for viral hepatitis diagnosis. Hepat Mon. 2014;14(4):e17632. doi: 10.5812/hepatmon.17632.

Banker DD. Viral hepatitis (Part-I). Indian J Med Sci. 2003;57(8):363-8.

Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12(Suppl 2):S2. doi: 10.1186/1471-2334-12-S2-S2.

Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318-27. doi: 10.1002/hep.26744

Zhang L, Gwinn M, Hu DJ. Viral hepatitis C gets personal - the value of human genomics to public health. Public Health Genomics. 2013;16(4):192-7. doi: 10.1159/000352014

Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, et al. Hepatitis C treatment: where are we now? Int J Gen Med. 2017;10:39-52. doi: 10.2147/IJGM.S127689

Yau AHL, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol. 2014;28(8):445-51. doi: 10.1155/2014/549624.

Sung PS, Racanelli V, Shin EC. CD8(+) T-Cell responses in acute hepatitis C virus infection. Front Immunol. 2014;5:266. doi: 10.3389/fimmu.2014.00266.

Holmes J, Thompson A, Bell S. Hepatitis C - an update. Aust Fam Physician. 2013;42(7):452-6. Available from: https://www.racgp.org.au/afp/2013/july/hepatitis-c/.

Huffman MM, Mounsey AL. Hepatitis C for primary care physicians. J Am Board Fam Med. 2014;27(2):284-91. doi: 10.3122/jabfm.2014.02

Isaacs D, Abdelaziz N, Keller M, Tibble J, Haq I. Measuring the response of extrahepatic symptoms and quality of life to antiviral treatment in patients with hepatitis C. Hepat Res Treat. 2013;2013:910519. doi: 10.1155/2013/910519.

Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer. 2016;11:29. doi: 10.1186/s13027-016-0076-7.

Garcovich S, Garcovich M, Capizzi R, Gasbarrini A, Zocco MA. Cutaneous manifestations of hepatitis C in the era of new antiviral agents. World J Hepatol. 2015;7(27):2740-8. doi: 10.4254/wjh.v7.i27.2740.

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):45-57. doi: 10.1016/j.jhep.2014.07.027.

Multimer D, Aghemo A, Diepolder H, Negro F, Robaeys G, Ryder S, et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420. doi: 10.1016/j.jhep.2013.11.003.

Martins T, Narciso-Schiavon JL, Schiavon L de L. Epidemiology of hepatitis C virus infection. Rev Assoc Med Bras. 2011;57(1):107-12. doi: 10.1590/S0104-42302011000100024

Kretzer IF, do Livramento A, da Cunha J, Gonçalves S, Tosin I, Spada C, et al. Hepatitis C worldwide and in Brazil: silent epidemic - data on disease including incidence, transmission, prevention, and treatment. Sci World J. 2014;1-10. doi: 10.1155/2014/827849.

Thompson AJ, Holmes JA. Treating hepatitis C - what’s new? Aust Prescr. 2015;38(6):191-7. doi: 10.18773/austprescr.2015.068.

Li H-C, Lo S-Y. Hepatitis C virus: virology, diagnosis and treatment. World J Hepatol. 2015;7(10):1377-89. doi: 10.4254/wjh.v7.i10.1377.

Houghton M. Hepatitis C: the next 25 years. Antivir Res. 2014;110:77-8. doi: 10.1016/j.antiviral.2014.06.018.

Wendt A, Adhoute X, Castellani P, Oules V, Ansaldi C, Benali S, et al. Chronic hepatitis C: future treatment. Clin Pharmacol. 2014;6:1-17. doi: 10.2147/CPAA.S30338.

Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol. 2014;20(23):7079-88. doi: 10.3748/wjg.v20.i23.7079

Cisneros-Garza LE. Nuevos avances en el manejo de la hepatitis C. Salud Publica Mex. 2011;53(1):S52–60.

American Association for the Study of Liver Diseases. Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C Welcome and Methods. 2014;(1):65. Available from: https://www.hcvguidelines.org/.

Laguno M, Von Wichmann MA, Van den Eynde E, Navarro J, Cifuentes C, Murillas J, et al. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Int J Infect Dis. 2016;53:46-51. doi: 10.1016/j.ijid.2016.10.028.

Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. 2014;6(1):4-15. doi: 10.1002/emmm.201303131.

Ahn J, Flamm SL. Frontiers in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (NY). 2014;10(2):90-100. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011382/.

Sparchez Z, Mocan T. Hepatocellular carcinoma occurrence and recurrence after antiviral treatment in HCV-related cirrhosis. Are outcomes different after direct antiviral agents? A review. J Gastrointestin Liver Dis. 2017;26(4):403-10. doi: 10.15403/jgld.2014.1121.264.hcv.

Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol. 2014;20(11):2839-53. doi: 10.3748/wjg.v20.i11.2839.

Hartfield M, Bull R, White PA, Lloyd A, Luciani F, Alizon S. Evidence that hepatitis C virus genome partly controls infection outcome. Evol Appl. 2014;7(5):533-47. doi: 10.1111/eva.12151.

Heim MH. Interferons and hepatitis C virus. Swiss Med Wkly. 2012;142:w13586. doi: 10.4414/smw.2012.13586.

Schooley RT. The fragile relationship between hepatitis C virus and its human host. Top Antivir Med. 2014;21(5):148-51. Availble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148848/.

Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Int J Med Sci. 2013;10(8):1015-21. doi: 10.7150/ijms.6402

Kanda T, Yokosuka O, Omata M. Antiviral therapy for “difficult-to-treat” hepatitis C virus-infected patients. Chin Med J (Engl). 2013;126(23):4568-74.

Trinks J, Hulaniuk ML, Redal MA, Flichman D. Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med. 2014;7:339-47. doi: 10.2147/PGPM.S52624.

Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Pharm. 2014;20(6):533-40. doi: 10.18553/jmcp.2014.20.6.533.

Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: a review. J Adv Res. 2017;8(2):89-97. doi: 10.1016/j.jare.2016.07.005.

Pol S, Corouge M, Sogni P. Oral antiviral therapies for chronic hepatitis C infection. Ther Adv Infect Dis. 2013;1(3):107-16. doi: 10.1177/2049936113488359.

Jimenez Galan R, Albacete Ramirez A, Monje Agudo P, Borrego Izquierdo Y, Morillo Verdugo R. New drugs in the treatment of chronic hepatitis C. Farm Hosp. 2014;38(3):231-47. doi: 10.7399/fh.2014.38.3.7314.

Sarrazin C, Manns M, Calleja JL, Garcia-Samaniego J, Forns X, Kaste R, et al. HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. PLoS One. 2016;11(12):e0168544. doi: 10.1371/journal.pone.0168544.

Vermehren J, Sarrazin C. New hepatitis C therapies in clinical development. Eur J Med Res. 2011;16(7):303-14. doi: 10.1186/2047-783X-16-7-303.

Morrow T. New hepatitis C drugs. Major killer disease comes under control. Manag Care. 2014;23(1):49-50.

Saludes V, Gonzalez V, Planas R, Matas L, Ausina V, Martro E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol. 2014;20(13):3431-42. doi: 10.3748/wjg.v20.i13.3431.

Marzio DL, Fenkel JM. Complementary and alternative medications in hepatitis C infection. World J Hepatol. 2014;6(1):9-16. doi: 10.4254/wjh.v6.i1.9.

Tamori A, Enomoto M, Kawada N. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm. 2016;2016:6841628. doi: 10.1155/2016/6841628.

Chayama K, Hayes CN. HCV Drug resistance challenges in Japan: the role of pre-existing variants and Emerging resistant strains in direct acting antiviral therapy. Viruses. 2015;7(10):5328-42. doi: 10.3390/v7102876

Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and management of hepatitis C. Am Fam Physician. 2015;91(12):835-42. Available from: https://www.aafp.org/afp/2015/0615/p835.pdf.

Chae HB, Park SM, Youn SJ. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. Sci World J. 2013;2013:1-9. doi: 10.1155/2013/704912.

Cabezas J, Llerena S, Puente A, Fábrega E, Crespo J. Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy. Rev Española Enfermedades Dig. 2015;108(7):421-9. doi: 10.17235/reed.2015.3894/2015.

Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511. doi: 10.1016/j. jhep.2018.03.026.

Younossi ZM, Stepanova M, Esteban R, Jacobson I, Zeuzem S, Sulkowski M, et al. Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity. Medicine (Baltimore). 2017;96(7):e5914. doi: 10.1097/MD.0000000000005914.

Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273-85. doi: 10.1016/j.jhep.2010.09.040.

Choo Q, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-62. doi: 10.1126/science.25233562.

Publicado
2019-10-15
Como Citar
Perlin, C., Groto, A., Perlin, G., & Salamanca, M. A. (2019). Hepatite C. Revista De Medicina, 98(5), 341-348. https://doi.org/10.11606/issn.1679-9836.v98i5p341-348
Seção
Artigos de Revisão/Review Articles